Alignment Healthcare shares rise 1.89% premarket after Invivyd aligns with FDA on rapid pathway for COVID-19 vaccine alternative.

Alignment Healthcare, Inc. rose 1.89% in premarket trading, with the company aligning with the U.S. FDA on a rapid pathway to full approval for its vaccine alternative monoclonal antibody candidate VYD2311. This candidate aims to protect American adults and adolescents from COVID-19, with a planned compact trial and attractive safety profile.